Spero Therapeutics (SPRO) director receives RSU and stock option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spero Therapeutics director Kathleen Tregoning received new equity awards. She was granted 10,000 restricted stock units, each convertible into one share of common stock upon vesting on June 23, 2027, subject to her continued service.
She also received stock options for 20,000 shares of common stock at an exercise price of $2.1500 per share, vesting in full on June 23, 2027 and expiring on June 23, 2036. Following these awards, she directly holds 85,000 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Tregoning Kathleen
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Grant/Award | Common Stock | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 20,000 shares (Direct, null);
Common Stock — 85,000 shares (Direct, null)
Footnotes (1)
- Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Key Figures
RSU grant: 10,000 shares
RSU vesting date: June 23, 2027
Stock options granted: 20,000 options
+4 more
7 metrics
RSU grant
10,000 shares
Restricted stock units granted on June 23, 2026
RSU vesting date
June 23, 2027
RSUs vest if service continues to this date
Stock options granted
20,000 options
Options on common stock granted June 23, 2026
Option exercise price
$2.1500 per share
Exercise price for 20,000 stock options
Option vesting date
June 23, 2027
Options vest and become exercisable in full
Option expiration date
June 23, 2036
Expiration of stock option term
Shares held after grant
85,000 shares
Total common stock directly held after transactions
Key Terms
restricted stock units ("RSUs"), Stock Option (right to buy), vesting, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 2.1500 per share."
vesting financial
"The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: 2.1500 for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The shares underlying this option will vest and become exercisable in full on June 23, 2027 and expire on June 23, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What equity awards did Spero Therapeutics (SPRO) director Kathleen Tregoning receive?
Kathleen Tregoning received 10,000 restricted stock units and stock options for 20,000 shares. The RSUs convert into common stock at vesting, and the options give her the right to buy common shares at a fixed exercise price.
When do Kathleen Tregoning’s new Spero Therapeutics (SPRO) RSUs vest?
The 10,000 restricted stock units vest on June 23, 2027, if she continues serving through that date. Each RSU then converts into one share of Spero Therapeutics common stock, increasing her direct share ownership when the vesting condition is met.
What are the key terms of Kathleen Tregoning’s new Spero Therapeutics stock options?
She received options on 20,000 shares of common stock with a $2.1500 exercise price. These options vest and become exercisable in full on June 23, 2027, and expire on June 23, 2036, provided she continues serving as a director.
Are Kathleen Tregoning’s Spero Therapeutics RSUs and options tied to continued service?
Yes. The RSUs vest on June 23, 2027, only if she continues serving through that date, and the options similarly vest and become exercisable in full on June 23, 2027, subject to her continued service as a director.